Screening tumor stage-specific candidate neoantigens in thyroid adenocarcinoma using integrated exome and transcriptome sequencing.
immune
machine learning
neoantigens
prognosis
thyroid carcinoma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
03
2023
accepted:
11
09
2023
medline:
23
10
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
epublish
Résumé
The incidence of thyroid carcinoma (THCA), the most common endocrine tumor, is continuously increasing worldwide. Although the overall prognosis of THCA is good, patients with distant metastases exhibit a mortality rate of 5-20%. To improve the diagnosis and overall prognosis of patients with thyroid cancer, we screened specific candidate neoantigen genes in early- and late-stage THCA by analyzing the transcriptome and somatic cell mutations in this study. The top five early-stage neoantigen-related genes (NRGs) were G protein-coupled receptor 4 [ In conclusion, the candidate NRGs identified in this study could potentially be used as therapeutic targets and diagnostic biomarkers for the development of novel broad spectrum therapeutic agents.
Sections du résumé
Background
The incidence of thyroid carcinoma (THCA), the most common endocrine tumor, is continuously increasing worldwide. Although the overall prognosis of THCA is good, patients with distant metastases exhibit a mortality rate of 5-20%.
Methods
To improve the diagnosis and overall prognosis of patients with thyroid cancer, we screened specific candidate neoantigen genes in early- and late-stage THCA by analyzing the transcriptome and somatic cell mutations in this study.
Results
The top five early-stage neoantigen-related genes (NRGs) were G protein-coupled receptor 4 [
Conclusion
In conclusion, the candidate NRGs identified in this study could potentially be used as therapeutic targets and diagnostic biomarkers for the development of novel broad spectrum therapeutic agents.
Identifiants
pubmed: 37854594
doi: 10.3389/fimmu.2023.1187160
pmc: PMC10579579
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1187160Informations de copyright
Copyright © 2023 Jia, Liang, Li, Qin, Li, Wang and Lu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Surg Oncol. 2021 Jul;28(7):3556-3565
pubmed: 33768394
J Exp Clin Cancer Res. 2015 Sep 11;34:102
pubmed: 26362431
J Nucl Med. 2018 Aug;59(8):1187-1194
pubmed: 29653980
Nat Cancer. 2022 Jun;3(6):681-695
pubmed: 35437317
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Front Oncol. 2022 Feb 24;12:804466
pubmed: 35280756
Bioinformatics. 2018 Nov 1;34(21):3771-3772
pubmed: 29790900
Lancet Diabetes Endocrinol. 2016 Jan;4(1):64-71
pubmed: 26608066
J Nucl Med. 2019 Jan;60(1):9-15
pubmed: 30190306
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885
Theranostics. 2021 May 24;11(15):7175-7187
pubmed: 34158843
Thyroid. 2021 Oct;31(10):1481-1493
pubmed: 34078123
Cancers (Basel). 2022 Oct 14;14(20):
pubmed: 36291817
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Curr Opin Endocrinol Diabetes Obes. 2017 Oct;24(5):332-336
pubmed: 28692457
Nat Biotechnol. 2013 Nov;31(11):999-1008
pubmed: 24142051
Nat Rev Clin Oncol. 2021 Apr;18(4):215-229
pubmed: 33473220
Nature. 2012 Feb 08;482(7385):400-4
pubmed: 22318521
Clin Trials. 2013 Aug;10(4):515-21
pubmed: 23610455
Front Genet. 2022 Aug 11;13:899384
pubmed: 36035114
J Clin Invest. 2015 Sep;125(9):3413-21
pubmed: 26258412
Science. 2015 Dec 11;350(6266):1387-90
pubmed: 26516200
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Mol Cancer. 2021 Dec 13;20(1):164
pubmed: 34903219
Nature. 2017 Dec 7;552(7683):116-120
pubmed: 29186113
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Am J Cancer Res. 2022 Aug 15;12(8):3581-3600
pubmed: 36119813
Front Immunol. 2019 Oct 17;10:2368
pubmed: 31681276
Stat Med. 2013 Dec 30;32(30):5381-97
pubmed: 24027076
Mol Cancer. 2021 Dec 6;20(1):159
pubmed: 34872567
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Genome Med. 2019 Nov 20;11(1):71
pubmed: 31747945
Int J Mol Sci. 2019 Sep 07;20(18):
pubmed: 31500315
Thyroid. 2014 Dec;24(12):1784-9
pubmed: 25208475
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
J Invest Dermatol. 2016 Jan;136(1):245-254
pubmed: 26763444
Front Endocrinol (Lausanne). 2020 May 22;11:82
pubmed: 32528402
Cancer Sci. 2017 Feb;108(2):170-177
pubmed: 27960040
Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646
pubmed: 36370105
Br J Haematol. 2020 Feb;188(3):367-382
pubmed: 31602633
Endocrine. 2021 Jun;72(3):644-659
pubmed: 33512656
Lupus. 2017 Aug;26(9):903-908
pubmed: 28121242
Endocrinol Metab Clin North Am. 2019 Mar;48(1):23-35
pubmed: 30717905
Transl Res. 2023 Feb;252:79-90
pubmed: 35948200
Endocr Rev. 2019 Feb 1;40(1):17-65
pubmed: 30184160
Ther Adv Med Oncol. 2019 Jun 06;11:1758835919855491
pubmed: 31217827
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Oncoimmunology. 2021 Sep 7;10(1):e1964189
pubmed: 34513318
BMJ. 2020 Jan 7;368:l6670
pubmed: 31911452
Ther Adv Med Oncol. 2021 Apr 22;13:17588359211008399
pubmed: 33995591
Pathobiology. 2018;85(1-2):117-129
pubmed: 29408820
Cancer Sci. 2022 Jun;113(6):2034-2043
pubmed: 35377528
Nat Commun. 2020 Sep 24;11(1):4835
pubmed: 32973173
Cancer Res. 2017 May 1;77(9):2179-2185
pubmed: 28432052
Annu Rev Med. 2014;65:125-37
pubmed: 24274180
Nat Med. 2018 Oct;24(10):1545-1549
pubmed: 30127394